P H A S E II C L I N I C A L T R I A L
In spring 2022, an inpatient Phase II Clinical Trial has been started to study safety and efficacy of
Neuro-Cells® treatment for Traumatic Spinal Cord Injury.
In September 2022, halfway patient inclusion was reached with no reported serious events until this point.
Randomized, placebo-controlled study
Early and late intervention cross-over design: the intervention group receives Neuro-Cells® immediately with six months follow-up. The placebo group will receive a placebo at first, but will also be treated and followed up with Neuro-Cells® after the intervention groups' primary endpoints are reached
Will involve 16 sub-acute patients that will be included six to eight weeks after sustaining trauma to the spinal cord
Under official approval from the Spanish ethical committee and competent authority Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS)
In collaboration with: Hospital Nacional de Parapléjicos, Toledo, Spain.